Valuation: Exelixis, Inc.

Market Cap 1.33TCr 6.9TCr 1.14TCr 1.06TCr 975.17Cr 1.83TCr 1,27300Cr 1.87TCr 13TCr 4.91TCr 64TCr 5TCr 4.89TCr 2,11200Cr P/E 2026 *
16.6x
P/E 2027 * 14.1x
Enterprise Value 1.26TCr 6.51TCr 1.08TCr 1TCr 920.59Cr 1.73TCr 1,20200Cr 1.76TCr 12TCr 4.64TCr 60TCr 4.72TCr 4.61TCr 1,99400Cr EV / Sales 2026 *
4.92x
EV / Sales 2027 * 4.07x
Free-Float
98.15%
Yield 2026 *
-
Yield 2027 * -
1 day-0.22%
1 week+4.59%
Current month-1.82%
1 month+2.66%
3 months+12.85%
6 months+19.92%
Current year+14.89%
1 week 137.4
Extreme 137.4
138.3
1 month 131.95
Extreme 131.95
140.56
Current year 104.72
Extreme 104.72
140.56
1 year 98.24
Extreme 98.24
140.56
3 years 50.71
Extreme 50.71
140.56
5 years 40
Extreme 40
140.56
10 years 40
Extreme 40
140.56
Manager TitleAgeSince
Chief Executive Officer 65 22/07/2010
Director of Finance/CFO 58 15/07/2015
Chief Operating Officer 63 01/02/2016
Director TitleAgeSince
Director/Board Member 70 01/02/2004
Director/Board Member 82 01/08/2004
Chairman 77 01/01/1998
Change 5-day change 1-year change 3-year change Capi.($)
-0.22%+4.59% - - 1.33TCr
+2.38%+3.43%+82.88%+115.89% 7.4TCr
+0.87%+17.34%+57.17%+97.28% 6.47TCr
-4.27%-0.99%-3.38%+475.61% 2.73TCr
-1.97%+20.38%-0.37%+0.48% 2.79TCr
+2.14%+12.21%+61.72%+27.26% 2.6TCr
-0.51%+5.73%+38.71%-12.79% 2TCr
-1.79%-4.84%+239.54%+414.48% 1.78TCr
+0.28%+2.69%+17.78%+528.82% 1.62TCr
-1.29%+6.09%+41.81%+154.45% 1.33TCr
Average -0.45%+6.18%+59.54%+200.17% 3.19TCr
Weighted average by Cap. +0.19%+8.21%+59.97%+161.45%

Financials

2026 *2027 *
Net sales 255.15Cr 1.32TCr 218.46Cr 203.83Cr 187.03Cr 351.44Cr 24TCr 358.36Cr 2.42TCr 942.6Cr 12TCr 958.04Cr 937.2Cr 41TCr 287.04Cr 1.49TCr 245.77Cr 229.31Cr 210.41Cr 395.37Cr 27TCr 403.15Cr 2.72TCr 1.06TCr 14TCr 1.08TCr 1.05TCr 46TCr
Net income 82Cr 425.36Cr 70Cr 66Cr 60Cr 113.03Cr 7.85TCr 115.26Cr 777.72Cr 303.17Cr 3.94TCr 308.14Cr 301.43Cr 13TCr 97Cr 505.01Cr 83Cr 78Cr 71Cr 134.2Cr 9.32TCr 136.84Cr 923.33Cr 359.93Cr 4.67TCr 365.83Cr 357.87Cr 15TCr
Net Debt -74Cr -385.88Cr -64Cr -59Cr -55Cr -102.54Cr -7.12TCr -104.56Cr -705.53Cr -275.03Cr -3.57TCr -279.54Cr -273.45Cr -12TCr -162.27Cr -841.08Cr -138.93Cr -129.63Cr -118.94Cr -223.5Cr -16TCr -227.9Cr -1.54TCr -599.46Cr -7.78TCr -609.28Cr -596.02Cr -26TCr
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Employees
1,077
Date Price Change Volume
19/26/19 R$137.40 -0.65% 4
18/26/18 R$138.30 +4.81% 1
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
53.69USD
Average target price
53.00USD
Spread / Average Target
-1.29%

Quarterly revenue - Rate of surprise